Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivosidenib - Servier

Next Previous
Drug Profile

Ivosidenib - Servier

Alternative Names: Tuoshuvo; AG-120; CS 3010; ivonib tablet; S-95031; TIBSOVO; Tibsovo; Tosuvo; Tuoshuwo

Latest Information Update: 21 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Bristol-Myers Squibb; CStone Pharmaceuticals; HOVON Foundation; Servier; University of Pittsburgh Medical Center
  • Class Antineoplastics; Cyclobutanes; Nitriles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma; Glioma; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Cholangiocarcinoma; Myelodysplastic syndromes
  • Phase III Chondrosarcoma
  • Phase II Glioma; Solid tumours

Most Recent Events

  • 02 Jun 2025 Launched for Acute myeloid leukaemia (Combination therapy, First-line therapy) in Japan (PO)
  • 27 Mar 2025 Preregistration for Acute myeloid leukaemia (First-line therapy, Combination therapy) in Japan (PO), before March 2025
  • 27 Mar 2025 Registered for Acute myeloid leukaemia (First-line therapy, Combination therapy) in Japan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top